P
Pratyaksha Wirapati
Researcher at Swiss Institute of Bioinformatics
Publications - 51
Citations - 6039
Pratyaksha Wirapati is an academic researcher from Swiss Institute of Bioinformatics. The author has contributed to research in topics: Colorectal cancer & Breast cancer. The author has an hindex of 21, co-authored 45 publications receiving 5088 citations. Previous affiliations of Pratyaksha Wirapati include Novartis.
Papers
More filters
Journal ArticleDOI
Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis
Christos Sotiriou,Pratyaksha Wirapati,Sherene Loi,Adrian L. Harris,Steve Fox,Johanna Smeds,Hans Nordgren,Pierre Farmer,Viviane Praz,Benjamin Haibe-Kains,Christine Desmedt,Denis Larsimont,Fatima Cardoso,Hans Peterse,Dimitry S.A. Nuyten,Marc Buyse,Marc J. van de Vijver,Jonas Bergh,Martine Piccart,Mauro Delorenzi +19 more
TL;DR: Gene expression grade index appeared to reclassify patients with histologic grade 2 tumors into two groups with high versus low risks of recurrence, which may improve the accuracy of tumor grading and thus its prognostic value.
Journal ArticleDOI
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
Pratyaksha Wirapati,Christos Sotiriou,Susanne Kunkel,Pierre Farmer,Sylvain Pradervand,Benjamin Haibe-Kains,Christine Desmedt,Michail Ignatiadis,Thierry Sengstag,Frédéric Schütz,Darlene R. Goldstein,Darlene R. Goldstein,Darlene R. Goldstein,Martine Piccart,Mauro Delorenzi +14 more
TL;DR: This meta-analysis of publicly available breast cancer gene expression and clinical data reveals connections between traditional prognostic factors, expression-based subtyping, and prognostic signatures, highlighting the important role of proliferation in breast cancer prognosis.
Journal ArticleDOI
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.
Christine Desmedt,Benjamin Haibe-Kains,Pratyaksha Wirapati,Marc Buyse,Denis Larsimont,Gianluca Bontempi,Mauro Delorenzi,Martine Piccart,Christos Sotiriou +8 more
TL;DR: Although proliferation is the strongest parameter predicting clinical outcome in the ER+/HER2− subtype and the common denominator of most prognostic gene signatures, immune response and tumor invasion seem to be the main molecular processes associated with prognosis in theER−/her2− and HER2+ subgroups, respectively.
Journal ArticleDOI
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.
Sherene Loi,Benjamin Haibe-Kains,Christine Desmedt,Pratyaksha Wirapati,Françoise Lallemand,Andrew Tutt,Cheryl Gillet,Paul Ellis,Kenneth Ryder,James F. Reid,Maria Grazia Daidone,M. A. Pierotti,Els M.J.J. Berns,Maurice P.H.M. Jansen,John A. Foekens,Mauro Delorenzi,Gianluca Bontempi,Martine Piccart,Christos Sotiriou +18 more
TL;DR: A gene classifier that can predict clinical outcome in tamoxifen-treated ER+ BC patients is developed and other genes and pathways that may elucidate further mechanisms that influence clinical outcome and prediction of response to tamoxIFen are proposed.
Journal ArticleDOI
Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer.
Hae Ock Lee,Hae Ock Lee,Yourae Hong,Yourae Hong,Hakki Emre Etlioglu,Yong Beom Cho,Yong Beom Cho,Valentina Pomella,Ben Van den Bosch,Jasper Vanhecke,Sara Verbandt,Hyekyung Hong,Jae Woong Min,Nayoung K.D. Kim,Nayoung K.D. Kim,Hye Hyeon Eum,Hye Hyeon Eum,Junbin Qian,Bram Boeckx,Diether Lambrechts,Petros Tsantoulis,Gert De Hertogh,Woosung Chung,Taeseob Lee,Taeseob Lee,Minae An,Minae An,Hyun Tae Shin,Je-Gun Joung,Min Hyeok Jung,Gunhwan Ko,Pratyaksha Wirapati,Seok-Hyung Kim,Hee Cheol Kim,Seong Hyeon Yun,Iain Beehuat Tan,Iain Beehuat Tan,Bobby Ranjan,Woo Yong Lee,Tae-You Kim,Jung Kyoon Choi,Young Joon Kim,Shyam Prabhakar,Sabine Tejpar,Woong-Yang Park,Woong-Yang Park +45 more
TL;DR: The collective view of the cellular landscape and intercellular interactions in colorectal cancer provide mechanistic information for the design of efficient immuno-oncology treatment strategies.